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ABSTRACT
Objective
Mutations in the KATP channel genes, ABCC8 and KCNJ11, are the most common cause of congenital 
hyperinsulinism. The diagnosis of KATP-hyperinsulinism is important for the clinical management of 
the condition. We aimed to determine the clinical features that help to identify KATP-
hyperinsulinism at diagnosis. 
Design
We studied 761 individuals with KATP-hyperinsulinism and 862 probands with hyperinsulinism of 
unknown aetiology diagnosed before 6 months of age. All were referred as part of routine clinical 
care. 
Methods
We compared the clinical features of KATP-hyperinsulinism and unknown hyperinsulinism cases. We 
performed logistic regression and ROC analysis to identify the features that predict KATP-
hyperinsulinism.
Results
Higher birth weight, diazoxide unresponsiveness and diagnosis in the first week of life were 
independently associated with KATP-hyperinsulinism (adjusted Odds Ratio 4.5 (95% CI, 3.4-5.9), 0.09 
(0.06-0.13) and 3.3 (2.0- 5.0) respectively). Birth weight and diazoxide unresponsiveness were 
additive and highly discriminatory for identifying KATP-hyperinsulinism (ROC area under the curve 
for birth weight 0.80, diazoxide responsiveness 0.77, and together 0.88, 95% CI 0.85-0.90). 86% born 
large for gestation and 78% born appropriate for gestation who did not respond to diazoxide 
treatment had KATP-hyperinsulinism. In contrast, of those individuals born small for gestation, none 
who were diazoxide responsive and only 4% of those who were diazoxide unresponsive had KATP-
hyperinsulinism.
Conclusions
Individuals with hyperinsulinism born appropriate or large for gestation and unresponsive to 
diazoxide treatment are most likely to have an ABCC8 or KCNJ11 mutation. These patients should be 
prioritised for genetic testing for KATP channel genes.
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Congenital hyperinsulinism (CHI) is a potentially life-threatening disorder characterised by 
inappropriately high levels of insulin at the time of hypoglycaemia. The incidence of CHI is estimated 
at 1 in 28,000 to 1 in 50,000 live births in European populations but rises to approximately 1 in 2,500 
in countries with high rates of consanguineous unions 1-3.
Mutations in approximately 15 genes have been reported to cause isolated CHI or a multi-system 
syndromic disease where CHI is a rare feature 4. Screening these genes identifies a mutation in 36-
69% of cases 5, 6. Inactivating mutations in the ABCC8 and KCNJ11 genes, encoding the SUR1 and 
Kir6.2 subunits of the pancreatic ATP-sensitive potassium (KATP) channel are responsible for 80-84% 
of confirmed monogenic cases of CHI 5,6.
Rapid screening of the KATP channel genes is critical for informing surgical and medical management 
of CHI 7. Identifying a dominantly-acting or bi-allelic ABCC8 or KCNJ11 mutation confirms a diagnosis 
of diffuse pancreatic disease which is preferentially managed with medical treatment whereas a 
paternally-inherited recessively-acting ABCC8 or KCNJ11 mutation suggest a focal pancreatic lesion 
which can be cured by lesionectomy 8.
In this study, we undertook genetic testing of the KATP channel genes in a large cohort of children 
with CHI presenting before the age of 6 months with the aim to assess whether clinical features at 
presentation could predict which individuals were most likely to have monogenic CHI due to a KATP 
channel mutation.
METHODS
Study population and genetic analysis
We studied 761 probands with a pathogenic or likely pathogenic mutation in ABCC8 (N=665) or 
KCNJ11 (N=96) identified at the Exeter Genomics Laboratory between 2002 and 2018. We also 
reviewed 862 patients with CHI of unknown genetic aetiology who were referred to our laboratory 
within the same period. In all of these patients, mutations in the ABCC8 and KCNJ11 genes had been 
excluded by Sanger sequencing or gene panel testing. 
Analysis of the coding regions and intron-exon boundaries of ABCC8 and KCNJ11 was performed 
using previously described methods 9, 10. When available, parental samples were tested to confirm 
the inheritance of ABCC8/KCNJ11 variants identified in the proband. Pathogenicity of variants was 
assessed according to ACMG guidelines 11.
Clinical information was provided at referral for genetic testing using a standardised request form 
and included sex, ethnicity, birth weight, gestational age at birth, age at diagnosis of CHI, 
biochemical measurements at diagnosis (including insulin and glucose), current treatment, response 
to diazoxide treatment if attempted and the presence of additional features. Although a precise, 
consensus definition of diazoxide responsiveness is lacking, diazoxide unresponsiveness in this study 
can be broadly defined as persistent hypoglycaemia despite treatment with maximal dose diazoxide 
indicating the need for additional therapies to achieve euglycaemia. Consanguinity was defined as 
the parents of the proband being related as second cousins or closer or if the proband was referred 
from a country with high reported rates of consanguinity 12.
Informed consent was obtained from the parents or guardians of all probands. This study was 
approved by the North Wales Research Ethics Committee (517/WA/0327). 
Statistical analysis
Birth weight Z score and corrected birth weight for sex and gestation were generated using WHO 
standards accessed through the Zanthro package in Stata 13. Small for gestational age (SGA) was 
Page 3 of 15 Accepted Manuscript published as EJE-21-0476.R1. Accepted for publication: 11-Oct-2021
Copyright © 2019 European Society of EndocrinologyDownloaded from Bioscientifica.com at 10/12/2021 02:34:42PM
via University of Exeter
defined as a birth weight lower than the 10th centile, and large for gestational age (LGA) was defined 
as a birth weight greater than the 90th centile. Age at diagnosis followed a skewed distribution, so 
was analysed categorically between those diagnosed in the first week of life and those diagnosed 
after the first week. As insulin (pmol/l) level followed a right skewed distribution, values were log 
transformed for the statistical analysis.
Individuals with an ABCC8 or KCNJ11 mutation were combined (referred to as KATP channel 
mutations hereafter) as no difference in clinical features was observed between the two genetic 
subgroups (Supplementary Table 1). Statistical analyses were performed to determine differences in 
the clinical features of patients with an unknown aetiology compared to patients with a KATP 
channel mutation. Two-tailed P values were calculated to determine statistical significance using 
Pearson’s chi-squared test for categorical variables, and Student’s T test for continuous variables. 
Univariate and multivariable logistic regression were used to assess which clinical features were 
independently predictive of having a KATP channel mutation. The area under the curve (AUC) of the 
receiver operator characteristic (ROC) was used to assess the discriminatory ability of the clinical 
features to identify individuals with a KATP channel mutation from those without a mutation. 
Stata/SE 16.0 (Stata Corp, College Station, TX, USA) was used to perform statistical analyses.
RESULTS
Seven of the clinical features studied were different between individuals with KATP CHI and those 
with CHI of unknown aetiology
Individuals with KATP channel mutations (n=761) had higher birthweights (mean 4333g vs 3512g, 
P=6 x 10-94, mean difference 821g, 95% CI 748g-894g), were more likely to be diagnosed in the first 
week of life (85% vs 72%, P=1 x 10-9), had a higher insulin level at diagnosis (mean 162.2pmol/l vs 
115.4pmol/l, P=1 x 10-8) and were less likely to respond to diazoxide, the mainstay treatment for CHI 
(32% vs 88%, P=2 x 10-84) compared to individuals with CHI of unknown genetic aetiology (n=862) 
(Table 1). They were more likely to be female (46% vs 36%, P=5 x 10-5), have consanguineous parents 
(52% vs 34%, P=2 x 10-12) and were less likely to be Caucasian (30% vs 52%, P=3 x 10-18) compared to 
CHI of unknown genetic aetiology. Glucose levels at presentation and the number of individuals with 
extra-pancreatic features at referral were similar between the two groups.
Birth weight and diazoxide unresponsiveness are the most discriminative, independent, and additive 
for identifying children with KATP CHI  
To identify the independent features that can help in discriminating KATP CHI from unknown cases, 
we performed a multivariable logistic regression analysis. We showed that higher birth weight, 
diazoxide unresponsiveness, and a diagnosis within the first 7 days of life were independent 
predictors of KATP CHI after adjustment for all variables (Table 2). We next performed ROC AUC 
analysis to assess the discriminatory ability of these variables. The ROC AUC for birth weight was 
0.80 (95% CI 0.77-0.82), 0.77 for diazoxide responsiveness (95% CI 0.74-0.80) and 0.59 for age at 
diagnosis (95% CI 0.57-0.62). Combining birth weight with diazoxide unresponsiveness increased the 
ROC AUC to 0.88 (95% CI 0.85-0.90). The addition of other factors (age at diagnosis, sex, ethnicity, 
consanguinity, insulin level) only marginally increased ROC AUC (0.89, 95% CI 0.87-0.91) over the 
combination of birth weight and diazoxide unresponsiveness (Table 2, Figure 1). To establish if our 
results were consistent across institutions that may have different standards in measuring these 
clinical features, we performed a sensitivity analysis with the two institutions that referred the most 
patients, along with the two countries with the most referred patients. We observed similar results 
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in this analysis, suggesting the presence of homogeneity in clinical features despite different patient 
populations and clinical practice (Supplementary Table 2).
Individuals born appropriate or large for gestation who did not respond to diazoxide had the highest 
likelihood of KATP CHI
Of the 220 individuals born large for gestational age who were unresponsive to diazoxide, 86% (95% 
CI 81%-91%) had KATP CHI, whilst no mutations were detected in those born small for gestational 
age who responded to diazoxide (Figure 2). Of the 179 individuals born appropriate for gestational 
age who were unresponsive to diazoxide, 78% (95% CI 71%-84%) had KATP CHI, whilst of the 389 
individuals born appropriate for gestational age who were responsive to diazoxide, only 18% (95% CI 
14%-22%) had KATP CHI. 
DISCUSSION
In this large study, we showed that simple clinical features such as birth weight and diazoxide 
responsiveness were independent and highly predictive for identifying individuals with KATP CHI 
from those with CHI of unknown aetiology.  
We show that patients with KATP CHI were ~830 g heavier compared to CHI due to unknown cause. 
Higher birth weight has been reported previously in patients with KATP CHI 14, 15 and with persistent 
CHI 16. However, previous studies generally did not include control cases without KATP mutations, 
were smaller in size, and were limited to single centres impacting on the ability to statistically assess 
the importance of birth weight for identifying KATP CHI. We also show that birthweight and other 
clinical features were comparable between ABCC8 and KCNJ11 CHI thus this finding is applicable to 
both KATP HI subtypes (Supplementary Table 1). The higher birth weight in the KATP CHI patients is 
in keeping with the onset of hyperinsulinism with KATP CHI in utero, as insulin acts as a growth 
factor in pregnancy 17. This is supported by the observation that most of the children with CHI are 
diagnosed in the first week of life. 
Diazoxide is the most common medical treatment for CHI which suppresses insulin secretion by 
binding to and opening the KATP channel 18. 78% of patients in our cohort who were unresponsive to 
diazoxide treatment had a KATP channel mutation, in keeping with the mutations leading an 
absence of channels or channels with disrupted function. Previous studies reported similar levels of 
diazoxide-unresponsiveness in patients with KATP CHI (5,6). Therefore, our finding is not 
unexpected, but due to large control cases, we were able to quantify the importance of lack of 
diazoxide response in identifying KATP CHI. Additionally, there was no difference in diazoxide 
responsiveness between patients with mutations in ABCC8 and KCNJ11 thus our findings are 
applicable to both genetic subtypes (Supplementary Table 1). Given that diazoxide is not universally 
available it will be important to perform further studies to assess whether responsiveness to other 
treatments (including somatostatin analogues) can help to predict KATP channel hyperinsulinism.
Our study has important clinical and research implications. Using the largest cohort of CHI cases 
referred from routine clinical practise, we robustly show that birth weight and response to diazoxide 
treatment can be used to help guide genetic testing in patients with CHI. Our cohort also included 
patients from multiple centres, of different ethnicities, and with different modes of inheritance for 
mutations in the KATP channel genes suggesting that our findings are applicable to patients world-
wide. More than 80% of cases born LGA or AGA who were unresponsive to diazoxide had KATP 
channel mutations and therefore every effort should be made to prioritise genetic testing in these 
individuals as finding a KATP mutation can guide clinical management (7). Current Pediatric 
Endocrine Society guidelines on hypoglycaemia lack recommendation on criteria that can be used to 
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prioritise patients for genetic testing for CHI (19). We believe our study provides important evidence 
in this regard which is especially relevant for resource-poor countries where access to genetic testing 
is limited 19. Furthermore, the findings from this study will help to prioritise patients for genetic 
discovery studies for patients with an unknown aetiology. Patients born large for gestational age 
who do not respond to diazoxide have an 86% chance of harbouring a mutation in a KATP channel 
gene (Figure 1). Therefore, patients in this category without a monogenic cause are good candidates 
to screen for pancreas-specific mosaic mutations and regulatory mutations affecting the KATP 
channel genes 20. 
We acknowledge that our study has some limitations. We used clinician reported assessment of 
diazoxide responsiveness thus it is likely to vary by referring clinician. However, the rate of diazoxide 
unresponsiveness in KATP CHI is similar to studies that used a single definition for this feature 5, 6. 
Furthermore, the lack of consistent definition will have reduced the discriminatory ability rather 
than inflated the estimate suggesting that a robust definition will provide improved or similar results 
to our study. Our study did not include comprehensive data on whether hyperinsulinism was 
transient or persistent in each patient as we wanted to identify features at diagnosis which could 
help predict a KATP channel mutation. However, enrichment of male and SGA patients in the 
unknown aetiology group suggests the presence of transient HI as reported by a recent study 21. We 
used clinician reporting and country of referral to infer consanguinity. Although this approach has 
been used previously 22, we recognise that this has likely increased the proportion of consanguinity 
reported in our cohort. Despite this, consanguinity was significantly enriched in patients with KATP 
hyperinsulinism. This suggests that a more accurate definition will further increase its utility in 
identifying KATP hyperinsulinism. Finally, our study finding is not applicable to cases of non-KATP 
monogenic CHI. We chose to focus on KATP CHI as they are responsible for more than 80% 
monogenic CHI and finding these mutations is of great clinical importance.
In conclusion, this study shows that birth weight, diazoxide responsiveness and presenting with CHI 
in the first week of life are independent and highly predictive for KATP channel mutations in patients 
with congenital hyperinsulinism. Patients born normal or large for gestational age who are 
unresponsive to diazoxide are most likely to have KATP channel mutations and should be referred 
for genetic testing. Our study provides robust results that will help to shape future guidelines on 
genetic testing for CHI and is applicable to patients worldwide.
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Figure 1 – Receiver operating curves analysis showing the discriminating ability of clinical features to 
identify individuals with KATP CHI from those with unknown aetiology. DR denotes diazoxide 
responsiveness. BW denotes birth weight. All includes birth weight, diazoxide responsiveness, age at 
diagnosis, sex, insulin level at diagnosis, ethnicity, consanguinity.
Figure 2 – Proportion of KATP Congenital Hyperinsulinism by diazoxide responsiveness and birth 
weight categories. Light grey bars represent the percentage number of individuals without a KATP 
channel mutation, dark grey bars represent the percentage number of cases with a KATP channel 
mutation. SGA = small for gestational age, AGA = appropriate for gestational age, LGA = large for 
gestational age.
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TABLE 1 -Characteristics of individuals with congenital hyperinsulinism with confirmed KATP channel 
mutations and of unknown aetiology. Categorical data are shown as n (%) whereas continuous data 
are shown as mean±SD. Number of patients [n] is presented where it differs from the total number 
in the cohort
Characteristics CHI with confirmed KATP 
channel mutations
CHI of unknown 
aetiology
P value
Values n Values n
Total n 761 862 -
Age at diagnosis - - 1 x 10-9
≤7 days 85% 644 72% 622 -
>7 days 15% 117 28% 240 -
Female sex 46% 352  36% 313 5x 10-5
Corrected birth weight (g) 4333±718 746 3512±762 843 6 x 10-94
Birth weight Z score 1.64±1.50 746 -0.13±1.66 843 1 x 10-95
Birth weight categories - - 8 x 10-93
LGA 56% 415/746 18% 151/843 -
AGA 44% 329/746 57% 478/ 843 -
SGA 0.3% 2/746 25% 214/843 -
Additional features 13% 102 18% 152 0.02*
White ethnicity 30% 224/736 52% 438/841 3 x 10-18
Consanguineous parents 52% 394  34% 296 2 x 10-12
Glucose (mmol/L) 1.6±0.7 653 1.7±0.8 740 0.02*
Insulin (pmol/L) 162.2±3.0 666 115.4± 2.9 715 1 x 10-8
Diazoxide responsive 32% 160/495 88% 521 2 x 10-84
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Characteristics Unadjusted Odds ratio (95% CI) P value
Adjusted Odds ratio 
(95% CI) P value
Diagnosed in first 
week of life 2 (1.6 -2.5) 3 x 10
-10 3.3 (2.0- 5.0) 2 x 10-6
Female sex 1.5 (1.2 – 1.8) 5 x 10-5 0.9 (0.6 – 1.3) 0.6
Corrected birth 
weight 4.4 (3.7 – 5.2) 3 x 10
-68 4.5 (3.4 – 5.9) 2 x 10-26
Caucasian ethnicity 2.4 (2.0 – 3.0) 9 x 10-18 1.5 (0.9 – 2.6) 0.1
Consanguinity 2.0 (1.6 – 2.4) 7 x 10-12 1.9 (1.1 – 3.3) 0.02
Insulin at diagnosis 1.9 (1.5 – 2.4) 9 x 10-9 0.7 (0.5 – 1.0) 0.08
Diazoxide 
responsive 0.08 (0.06 – 0.11) 2 x 10
-65 0.09 (0.06 – 0.13) 2 x 10-36
 
Table 2 – Odds ratios for clinical characteristics from logistic regression model for identifying 
individuals with KATP CHI from CHI of unknown aetiology. Table shows odds ratio (95% confidence 
interval) for univariate and multivariate analysis after adjusting for all variables.
Page 13 of 15 Accepted Manuscript published as EJE-21-0476.R1. Accepted for publication: 11-Oct-2021
Copyright © 2019 European Society of EndocrinologyDownloaded from Bioscientifica.com at 10/12/2021 02:34:42PM
via University of Exeter
Supplementary Table 1 – Characteristics of individuals with congenital hyperinsulinism caused by mutations in ABCC8 and KCNJ11. Categorical data are shown as n (%) whereas continuous 
data are shown as mean (SD). *P values are above the Bonferroni corrected threshold for multiple comparison (0.05/8 = 0.006). Number of patients [n] is shown In square brackets where it 
differs from the total number in the cohort.
Characteristics CHI with confirmed ABCC8 mutation CHI with confirmed KCNJ11 mutation P value
N 665 96 -
Age at diagnosis - - 0.88
≤7 days 562 (85%) 82 (85%) -
>7 days 103 (15%) 14 (15%) -
Female sex 313 (47%) 39 (41%) 0.27
Corrected birth weight (g) [n] 4331 (706) [650] 4341 (797) 0.90
Birth weight Z score [n] 1.64 (1.47) [650] 1.65 (1.66) 0.93
Birth weight categories - - 0.19
LGA 365 (56%) [650] 50 (52%) -
AGA 284 (44%) [650] 45 (47%) -
SGA 1 (0.2%) [650] 1 (1%) -
Additional features 84 (13%) 18 (19%) 0.11
White ethnicity [n] 195 (30%) [642] 29 (31%) [94] 0.91
Consanguineous parents 343 (52%) 51 (53%) 0.83
Glucose (mmol/L) [n] 1.6 (0.7) [577] 1.6 (0.6) [76] 0.90
Insulin (pmol/L) [n] 161.2 (3.0) [588] 170.0 (2.9) [78] 0.69
Diazoxide responsive [n] 133 (31%) [423] 27 (38%) [72] 0.34
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Supplementary Table 2 - Sensitivity analysis showing the utility of clinical features to discriminate between KATP CHI and CHI of an unknown aetiology in the two countries and institutes 
with the most referrals. ROC AUC = Receiver Operating Characteristic Area Under the Curve
No with KATP 
HI/total HI
ROC AUC for 
corrected birth 
weight alone (95% 
CI)

















Whole cohort 761/1685 0.80 (0.77 – 0.82) 0.77 (0.74 – 0.80) 0.88 (0.85 – 0.90) 0.89 (0.87 – 0.91)
Patients from the UK 173/531 0.85 (0.80 – 0.89) 0.84 (0.79 – 0.88) 0.94 (0.91 – 0.96) 0.93 (0.91 – 0.96)
Patients from Turkey 102/208 0.86 (0.80 – 0.92) 0.75 (0.68 – 0.82) 0.89 (0.84 – 0.95) 0.90 (0.85 – 0.96)
Patients referred 
from GOSH
116/283 0.81 (0.74 – 0.87) 0.84 (0.79 – 0.90) 0.91 (0.87 – 0.96) 0.93 (0.88 – 0.97)
Patients referred 
from Manchester
35/90 0.89 (0.81 – 0.98) 0.80 (0.69 – 0.91) 0.94 (0.87 – 1.00) 0.93 (0.86 – 0.99)
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